Home DNA Damage/DNA Repair Alkylating Agent inhibitor Cyclophosphamide Monohydrate

solo para uso en investigación

Cyclophosphamide Monohydrate Alkylating Agent

Cat. No.: S2057

Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.Cyclophosphamide (NSC-26271) Monohydrate can be used to induce animal models of Anemia.
Cyclophosphamide Monohydrate Alkylating Agent inhibitor Chemical Structure

Estructura química

Peso molecular: 279.1

Saltar a

Control de calidad (Quality Control)

Lote: Pureza: 99.20%
99.20

Cultivo celular, tratamiento y concentración de trabajo
(Cell Culture, Treatment & Working Concentration)

Líneas celulares Tipo de ensayo Concentración Tiempo de incubación Formulación Descripción de la actividad PMID
HL60 cells Cytotoxicity assay Cytotoxicity against human HL60 cells by MTT assay, IC50=8.79 μM 20850303
BALB/c 3T3 cells Cytotoxicity assay In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells, IC50=37.6 μM 9873412
BALB/c 3T3 Cytotoxicity assay In vitro cytotoxicity against BALB/c 3T3 cells, IC50 = 37.6 μM. 7877150
T-cells Immunosuppressive assay 100 mg/kg 8 days Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as T cells suppression at 100 mg/kg, ip treated 8 days before infection for 4 weeks measured 14 days post infection by flow cytometry 18268085
B-cells Immunosuppressive assay 100 mg/kg 8 days Immunosuppressive activity against MAV-1 infected BALB/c mouse assessed as B cells suppression at 100 mg/kg, ip treated 8 days before infection for 4 weeks measured 14 days post infection by flow cytometry 18268085
U87 MG Antitumor assay 80 mg/kg Antitumor activity in human U87 MG cells xenografted mouse at 80 mg/kg, iv administered in Q2D x 5 schedule 18450456
MX1 Antitumor assay 120 mg/kg up to 3 weeks Antitumor activity against human MX1 cells xenografted in nude mouse adjuvant model assessed as increase in mouse survival time at 120 mg/kg, po BID measured up to 3 weeks 20726512
U87MG Anticancer assay 80 mg/kg 6 days Anticancer activity against human U87MG cells xenografted in athymic mouse assessed as tumor suppression at 80 mg/kg, iv Q2D for 6 days 21106377
NCI-H522 Antitumor assay 50 mg/kg 28 days Antitumor activity against human NCI-H522 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 50 mg/kg, ig administered once daily for 28 days relative to control 28092860
U2932 Antitumor assay 50 mg/kg 5 consecutive days Antitumor activity against human U2932 cells xenografted in SCID mouse assessed as reduction in tumor burden at 50 mg/kg, ip administered for 5 consecutive days measured up to day 40 post cell injection 28605593
MDA-MB-231 Cytotoxicity assay 48 hr Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells after 48 hr by MTT assay, IC50 = 0.09 μM. ChEMBL
K562 Cytotoxicity assay 48 hr Cytotoxicity against Homo sapiens (human) K562 cells after 48 hr by MTT assay, IC50 = 0.15 μM. ChEMBL
K562 Antiproliferative assay 48 hr Antiproliferative activity against Homo sapiens (human) K562 cells after 48 hr by MTT assay, IC50 = 0.153 μM. ChEMBL
MCF7 Cytotoxicity assay 48 hr Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay, IC50 = 10 mM. 19372630
HepG2 Cytotoxicity assay 48 hr Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by MTT assay, IC50 = 0.24 μM. ChEMBL
Haga clic para ver más datos experimentales de líneas celulares

Información química, almacenamiento y estabilidad (Chemical Information, Storage & Stability)

Peso molecular 279.1 Fórmula

C7H15Cl2N2O2P.H2O

 Almacenamiento (Desde la fecha de recepción)
Nº CAS 6055-19-2 Descargar SDF Almacenamiento de soluciones madre

Sinónimos NSC-26271 Monohydrate Smiles C1CNP(=O)(OC1)N(CCCl)CCCl.O

Solubilidad (Solubility)

In vitro
Lote:

DMSO : 55 mg/mL (197.06 mM)
(El DMSO contaminado con humedad puede reducir la solubilidad. Usar DMSO fresco y anhidro.)

Water : 55 mg/mL

Ethanol : 55 mg/mL

Calculadora de Molaridad

Masa Concentración Volumen Peso molecular
Calculadora de Dilución Calculadora de Peso Molecular

In vivo
Lote:

Calculadora de formulación in vivo (Solución clara)

Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)

mg/kg g μL

Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Resultados del cálculo:

Concentración de trabajo: mg/ml;

Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.

Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.

Mecanismo de acción (Mechanism of Action)

In vitro

Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Cyclophosphamide treatment enhances apoptosis and decreases homeostatic proliferation of regulatory T cells. Cyclophosphamide downregulates the expression of GITR and FoxP3, which are involved in the suppressive activity of T(REGs).

Cyclophosphamide increases CYP3A4, CYP2C8, and CYP2C9 protein levels in primary human hepatocyte cultures, which thereby enhances their own rates of 4-hydroxylation in the cultured hepatocytes.

Cyclophosphamide has produced mutations in base-pair substituting strains of Salmonella tryphimurium in the presence of metabolic activation, but it has been shown to be negative in the E. coli chromotest. Cyclophosphamide has been shown to produce gene mutations, chromosome aberrations, micronuclei and sister chromatid exchanges in a variety of cultured cells in the presence of metabolic activation as well as sister chromatid exchanges without metabolic activation.

In vivo

Cyclophosphamide has also produced chromosome damage and micronuclei in rats, mice and Chinese hamsters, and gene mutations in the mouse spot test and in the transgenic lacZ construct of Muta Mouse.

Cyclophosphamide, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhances the vaccine's potential to delay tumor growth in neu transgenic mice. Cyclophosphamide mediates its effects by enhancing the efficacy of the vaccine rather than via a direct cytolytic effect on cancer cells.

Referencias
  • [4] https://pubmed.ncbi.nlm.nih.gov/11325840/
  • [5] https://pubmed.ncbi.nlm.nih.gov/35409194/
  • [6] https://pubmed.ncbi.nlm.nih.gov/34385713/
  • [7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123643/
  • [8] https://pubmed.ncbi.nlm.nih.gov/21530682/

Aplicaciones (Applications)

Métodos Biomarcadores Imágenes PMID
Western blot PTEN / pAkt / Caspase 3 / GAPDH Caspase 3 / Cleaved-Caspase 3 / Cleaved-PARP / Tubulin Nuclear AIF / Cytosolic AIF / TBP / GAPDH LC3B I / LC3B II / GAPDH
S2057-WB-1
23874108
Growth inhibition assay Cell Viability Tumor Volume Tumor Volume
S2057-Growth-inhibition-assay-1
31429028
IHC tumor cell invasion TUNEL / Caspase 3 PTEN / pAkt / PCNA ovary of mice Caspase-3
S2057-IHC-1
23874108
Immunofluorescence pAKT / pERK Ki-67 / UPK3 / KRT5 / pERK Ki-67 / KRT14 / KRT5 autophagy levels
S2057-IF-1
31654636

Información del ensayo clínico (Clinical Trial Information)

(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)

Número NCT Reclutamiento Condiciones Patrocinador/Colaboradores Fecha de inicio Fases
NCT06186700 Active not recruiting
Breast Cancer Female
Mansoura University
 December 25 2023 Phase 2
NCT06085742 Recruiting
Breast Cancer
University of Illinois at Chicago
 November 22 2023 Phase 2
NCT05800041 Not yet recruiting
Gout Tophus
RenJi Hospital|Westlake Therapeutics
 April 10 2023 Early Phase 1

Preguntas frecuentes (Frequently Asked Questions)

Pregunta 1:
Why does it show no activity in vitro assays?

Respuesta:
The activity of this compound in vitro is controversial and has not been fully determined. It is a prodrug and may need Cytochrome P450 to convert it to the active form: 4-hydroxy cyclophosphamide. It is widely used in vivo, if you are going to use it in vitro, you may need to supplement Cytochrome P450 exogenously.